#What happened with Parabilis Medicines
Parabilis Medicines achieved a significant milestone by successfully completing one of the largest biotech initial public offerings in 2026. The company priced 33.5 million shares at $20 each, raising an impressive $670 million in gross proceeds. This pricing surpassed the initial projected share price range of $17 to $19 and expanded the number of shares from an originally planned 25 million.
Shares of Parabilis will trade on Nasdaq under the ticker PBLS starting June 10, 2026.
#Why was the IPO upsized?
Initially, Parabilis anticipated selling 25 million shares within the $17 to $19 price range. If the IPO had proceeded as originally planned, it would have raised approximately $450 million at the midpoint. However, with the upsized offering yielding $670 million, Parabilis exceeded its expectations by nearly 50%, setting a new record for biotech IPO proceeds. This milestone breaks previous records held by Kailera Therapeutics, which raised $625 million.
#What are the funding details?
In addition to the public offering, Parabilis secured a concurrent private placement with Regeneron Pharmaceuticals, totaling $75 million. Regeneron's shares were priced at $18 each, slightly below the IPO price. Collectively, this means Parabilis raised an astounding $745 million from both the IPO and private placement, enhancing its financial capabilities significantly.
#What does Parabilis Medicines specialize in?
Founded in 2015 in Cambridge, Massachusetts, Parabilis Medicines originally operated under the name Fog Pharmaceuticals. The company's primary innovation is the Helicon platform, which focuses on stabilized helical peptide therapeutics designed to target complex intracellular protein interactions. This innovative approach allows for treatment methods that traditional small molecules and antibodies struggle to achieve. The company primarily focuses on oncology and other serious diseases, indicating its commitment to addressing critical health challenges.
Currently in the clinical stage, Parabilis has not yet received approval for any of its drug candidates. The substantial financial resources raised through the IPO and the private placement will be crucial for funding ongoing clinical trials, regulatory activities, and operational needs, as the company navigates what may be a lengthy development timeline.